Table 6. Early clinical trials of PI3K pathway inhibitors in association with another targeted therapy in OC
From: The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
Trial phase and/or population feature | Treatment | No. of OC patients | Efficacy | Reference |
|---|---|---|---|---|
Phase II | Temsirolimus + bevacizumab | 31 | RR = 12% | Morgan et al.[64] |
Randomized II | Bevacizumab +/− everolimus | 150 | Improved RR with the combination (19% vs. 9%) | Tew et al.[67] |
No impact on PFS or OS | ||||
Phase I | Everolimus + bevacizumab + panitumumab (an EGFR antibody) | 4 | 3 cases of SD for 11 to >40 months | Vlahovic et al.[56] |
Phase Ib, OC expansion cohort with biomarker selected (low-RAS signature) | IGF-1R antibody, dalo tuzumab + ridaforolimus or MK2206 (Akt inhibitor) | 12 | 3 cases of SD | Brana et al.[59] |
Phase Ib, KRAS-mutated OC expansion cohort | BYL719 (PI3K inhibitor) + MEK162 | 4 | 3 cases of confirmed PR | Juric et al.[61] |
RAS-mutated OC | PI3K inhibitor + MEK inhibitor (NOS) | 13 | 6 cases of PR | Spreafico et al.[62] |
ER + and/or PgR + OC | Everolimus + letrozole | 10 | 2 demonstrated minimal response or SD >6 months | Wheler et al.[70] |